Immunomodulatory and anti-inflammatory properties of artesunate in experimental colitis

Z. Yang, J. Ding, C. Yang, Y. Gao, Xuhang Li, X. Chen, Y. Peng, J. Fang, S. Xiao

Research output: Contribution to journalArticle

Abstract

Background: Inflammatory bowel disease is a chronic and idiopathic gastrointestinal inflammation mediated by disregulated immune responses. Artemisinin (a chemical from a traditional Chinese herbal medicine Artemisia annua L.) and its derivatives have been proven to exhibit anti-inflammatory and immunomodulatory effects in the treatment of systemic lupus erythematosus and rheumatoid arthritis with low side-effects. This study is aimed to evaluate the potential therapeutic value of artesunate for inflammatory bowel disease. Methods: Murine colitis was induced by either oral administration of dextran sulfate sodium salt (DSS) or intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid (TNBS) or oxazolone. Mice were treated with artesunate (150mg/kg/day). Peritoneal macrophages were stimulated with lipopolysaccharide (LPS) in the presence or absence of artesunate. Changes in cytokines or proteins of interests were analyzed by enzyme-linked immunosorbent assay (ELISA) or SDS-PAGE/Western blot. Results: Artesunate significantly ameliorated DSS colitis and TNBS colitis (but not oxazolone colitis), including reduced weight loss and disease activity, as well as macroscopic and microscopic colonic injury. The expression of NF-tcBp65 and p-ItcB-a were reduced in artesunate treated TNBS colitis compared with untreated. The levels of IFN-γ, IL-17, and TNF-a were significantly decreased in artesunate treated TNBS colitis or DSS colitis. Furthermore, in vitro artesunate treatment significantly inhibited TNF-α production by LPS-activated macrophages. Conclusions: Artesunate suppresses TNF-a expression in vitro and in vivo as well as T-helper (Th)1/Th17 responses in TNBS colitis model. Our data suggest a novel clinical application of artesunate as a potential therapy for Crohn's disease.

Original languageEnglish (US)
Pages (from-to)4541-4551
Number of pages11
JournalCurrent Medicinal Chemistry
Volume19
Issue number26
DOIs
StatePublished - Sep 2012

Fingerprint

Colitis
Anti-Inflammatory Agents
Sulfonic Acids
Trinitrobenzenes
Dextran Sulfate
Oxazolone
Salts
Macrophages
Inflammatory Bowel Diseases
Lipopolysaccharides
Artemisia annua
artesunate
Immunosorbents
Interleukin-17
Herbal Medicine
Peritoneal Macrophages
Therapeutics
Crohn Disease
Systemic Lupus Erythematosus
Oral Administration

Keywords

  • Animal model
  • Artesunate
  • Colitis
  • Crohn's disease
  • Immunomodulation
  • Inflammatory bowel disease
  • Macrophage
  • NF-KB
  • Pro-inflammatory cytokines
  • TNF-a

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Immunomodulatory and anti-inflammatory properties of artesunate in experimental colitis. / Yang, Z.; Ding, J.; Yang, C.; Gao, Y.; Li, Xuhang; Chen, X.; Peng, Y.; Fang, J.; Xiao, S.

In: Current Medicinal Chemistry, Vol. 19, No. 26, 09.2012, p. 4541-4551.

Research output: Contribution to journalArticle

Yang, Z, Ding, J, Yang, C, Gao, Y, Li, X, Chen, X, Peng, Y, Fang, J & Xiao, S 2012, 'Immunomodulatory and anti-inflammatory properties of artesunate in experimental colitis', Current Medicinal Chemistry, vol. 19, no. 26, pp. 4541-4551. https://doi.org/10.2174/092986712803251575
Yang, Z. ; Ding, J. ; Yang, C. ; Gao, Y. ; Li, Xuhang ; Chen, X. ; Peng, Y. ; Fang, J. ; Xiao, S. / Immunomodulatory and anti-inflammatory properties of artesunate in experimental colitis. In: Current Medicinal Chemistry. 2012 ; Vol. 19, No. 26. pp. 4541-4551.
@article{e4f46635c6f24ae695b2181ffc1537c3,
title = "Immunomodulatory and anti-inflammatory properties of artesunate in experimental colitis",
abstract = "Background: Inflammatory bowel disease is a chronic and idiopathic gastrointestinal inflammation mediated by disregulated immune responses. Artemisinin (a chemical from a traditional Chinese herbal medicine Artemisia annua L.) and its derivatives have been proven to exhibit anti-inflammatory and immunomodulatory effects in the treatment of systemic lupus erythematosus and rheumatoid arthritis with low side-effects. This study is aimed to evaluate the potential therapeutic value of artesunate for inflammatory bowel disease. Methods: Murine colitis was induced by either oral administration of dextran sulfate sodium salt (DSS) or intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid (TNBS) or oxazolone. Mice were treated with artesunate (150mg/kg/day). Peritoneal macrophages were stimulated with lipopolysaccharide (LPS) in the presence or absence of artesunate. Changes in cytokines or proteins of interests were analyzed by enzyme-linked immunosorbent assay (ELISA) or SDS-PAGE/Western blot. Results: Artesunate significantly ameliorated DSS colitis and TNBS colitis (but not oxazolone colitis), including reduced weight loss and disease activity, as well as macroscopic and microscopic colonic injury. The expression of NF-tcBp65 and p-ItcB-a were reduced in artesunate treated TNBS colitis compared with untreated. The levels of IFN-γ, IL-17, and TNF-a were significantly decreased in artesunate treated TNBS colitis or DSS colitis. Furthermore, in vitro artesunate treatment significantly inhibited TNF-α production by LPS-activated macrophages. Conclusions: Artesunate suppresses TNF-a expression in vitro and in vivo as well as T-helper (Th)1/Th17 responses in TNBS colitis model. Our data suggest a novel clinical application of artesunate as a potential therapy for Crohn's disease.",
keywords = "Animal model, Artesunate, Colitis, Crohn's disease, Immunomodulation, Inflammatory bowel disease, Macrophage, NF-KB, Pro-inflammatory cytokines, TNF-a",
author = "Z. Yang and J. Ding and C. Yang and Y. Gao and Xuhang Li and X. Chen and Y. Peng and J. Fang and S. Xiao",
year = "2012",
month = "9",
doi = "10.2174/092986712803251575",
language = "English (US)",
volume = "19",
pages = "4541--4551",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "26",

}

TY - JOUR

T1 - Immunomodulatory and anti-inflammatory properties of artesunate in experimental colitis

AU - Yang, Z.

AU - Ding, J.

AU - Yang, C.

AU - Gao, Y.

AU - Li, Xuhang

AU - Chen, X.

AU - Peng, Y.

AU - Fang, J.

AU - Xiao, S.

PY - 2012/9

Y1 - 2012/9

N2 - Background: Inflammatory bowel disease is a chronic and idiopathic gastrointestinal inflammation mediated by disregulated immune responses. Artemisinin (a chemical from a traditional Chinese herbal medicine Artemisia annua L.) and its derivatives have been proven to exhibit anti-inflammatory and immunomodulatory effects in the treatment of systemic lupus erythematosus and rheumatoid arthritis with low side-effects. This study is aimed to evaluate the potential therapeutic value of artesunate for inflammatory bowel disease. Methods: Murine colitis was induced by either oral administration of dextran sulfate sodium salt (DSS) or intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid (TNBS) or oxazolone. Mice were treated with artesunate (150mg/kg/day). Peritoneal macrophages were stimulated with lipopolysaccharide (LPS) in the presence or absence of artesunate. Changes in cytokines or proteins of interests were analyzed by enzyme-linked immunosorbent assay (ELISA) or SDS-PAGE/Western blot. Results: Artesunate significantly ameliorated DSS colitis and TNBS colitis (but not oxazolone colitis), including reduced weight loss and disease activity, as well as macroscopic and microscopic colonic injury. The expression of NF-tcBp65 and p-ItcB-a were reduced in artesunate treated TNBS colitis compared with untreated. The levels of IFN-γ, IL-17, and TNF-a were significantly decreased in artesunate treated TNBS colitis or DSS colitis. Furthermore, in vitro artesunate treatment significantly inhibited TNF-α production by LPS-activated macrophages. Conclusions: Artesunate suppresses TNF-a expression in vitro and in vivo as well as T-helper (Th)1/Th17 responses in TNBS colitis model. Our data suggest a novel clinical application of artesunate as a potential therapy for Crohn's disease.

AB - Background: Inflammatory bowel disease is a chronic and idiopathic gastrointestinal inflammation mediated by disregulated immune responses. Artemisinin (a chemical from a traditional Chinese herbal medicine Artemisia annua L.) and its derivatives have been proven to exhibit anti-inflammatory and immunomodulatory effects in the treatment of systemic lupus erythematosus and rheumatoid arthritis with low side-effects. This study is aimed to evaluate the potential therapeutic value of artesunate for inflammatory bowel disease. Methods: Murine colitis was induced by either oral administration of dextran sulfate sodium salt (DSS) or intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid (TNBS) or oxazolone. Mice were treated with artesunate (150mg/kg/day). Peritoneal macrophages were stimulated with lipopolysaccharide (LPS) in the presence or absence of artesunate. Changes in cytokines or proteins of interests were analyzed by enzyme-linked immunosorbent assay (ELISA) or SDS-PAGE/Western blot. Results: Artesunate significantly ameliorated DSS colitis and TNBS colitis (but not oxazolone colitis), including reduced weight loss and disease activity, as well as macroscopic and microscopic colonic injury. The expression of NF-tcBp65 and p-ItcB-a were reduced in artesunate treated TNBS colitis compared with untreated. The levels of IFN-γ, IL-17, and TNF-a were significantly decreased in artesunate treated TNBS colitis or DSS colitis. Furthermore, in vitro artesunate treatment significantly inhibited TNF-α production by LPS-activated macrophages. Conclusions: Artesunate suppresses TNF-a expression in vitro and in vivo as well as T-helper (Th)1/Th17 responses in TNBS colitis model. Our data suggest a novel clinical application of artesunate as a potential therapy for Crohn's disease.

KW - Animal model

KW - Artesunate

KW - Colitis

KW - Crohn's disease

KW - Immunomodulation

KW - Inflammatory bowel disease

KW - Macrophage

KW - NF-KB

KW - Pro-inflammatory cytokines

KW - TNF-a

UR - http://www.scopus.com/inward/record.url?scp=84868007878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868007878&partnerID=8YFLogxK

U2 - 10.2174/092986712803251575

DO - 10.2174/092986712803251575

M3 - Article

C2 - 22834815

AN - SCOPUS:84868007878

VL - 19

SP - 4541

EP - 4551

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 26

ER -